MX2020011050A - Imidazopiridinas útiles como desacopladores mitocondriales. - Google Patents
Imidazopiridinas útiles como desacopladores mitocondriales.Info
- Publication number
- MX2020011050A MX2020011050A MX2020011050A MX2020011050A MX2020011050A MX 2020011050 A MX2020011050 A MX 2020011050A MX 2020011050 A MX2020011050 A MX 2020011050A MX 2020011050 A MX2020011050 A MX 2020011050A MX 2020011050 A MX2020011050 A MX 2020011050A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- formula
- useful
- mitochondrial
- uncouplers
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/18—Oxygen or sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/16—Halogen atoms; Nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Gastroenterology & Hepatology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862660880P | 2018-04-20 | 2018-04-20 | |
| PCT/US2019/028555 WO2019204816A1 (en) | 2018-04-20 | 2019-04-22 | Imidazopyridines useful as mitochondrial uncouplers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020011050A true MX2020011050A (es) | 2021-03-09 |
Family
ID=67139787
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020011050A MX2020011050A (es) | 2018-04-20 | 2019-04-22 | Imidazopiridinas útiles como desacopladores mitocondriales. |
| MX2020011049A MX2020011049A (es) | 2018-04-20 | 2019-04-22 | Oxadiazolopirazinas y oxadiazolopiridinas útiles como desacopladores mitocondriales. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020011049A MX2020011049A (es) | 2018-04-20 | 2019-04-22 | Oxadiazolopirazinas y oxadiazolopiridinas útiles como desacopladores mitocondriales. |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US20210253594A1 (https=) |
| EP (3) | EP3781572A1 (https=) |
| JP (3) | JP2021522327A (https=) |
| KR (3) | KR20210003831A (https=) |
| CN (3) | CN112262141A (https=) |
| AU (2) | AU2019256722A1 (https=) |
| BR (2) | BR112020021466A2 (https=) |
| CA (2) | CA3097751A1 (https=) |
| IL (2) | IL278070A (https=) |
| MX (2) | MX2020011050A (https=) |
| WO (3) | WO2019204813A1 (https=) |
| ZA (2) | ZA202006295B (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112262141A (zh) * | 2018-04-20 | 2021-01-22 | 弗吉尼亚理工大学知识产权有限公司 | 可用作线粒体解偶联剂的咪唑吡啶 |
| WO2020191503A1 (en) * | 2019-03-27 | 2020-10-01 | Algernon Pharmaceuticals Inc. | Methods and uses of bromantane and derivatives thereof for treating lung disease, fatty liver disease, and kidney disorders |
| CA3189027A1 (en) | 2020-07-11 | 2022-01-20 | Pfizer Inc. | Antiviral heteroaryl ketone derivatives |
| US11351149B2 (en) | 2020-09-03 | 2022-06-07 | Pfizer Inc. | Nitrile-containing antiviral compounds |
| EP4482494A4 (en) * | 2022-02-21 | 2026-02-25 | Univ Colorado Regents | RE-SENSITIZATION OF MULTI-DRUG-RESISTANT GRAM-NEGATIVE (MDR) BACTERIA TO COLISTIN USING IONOPHORES |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2501680A1 (fr) | 1981-03-12 | 1982-09-17 | Elf Aquitaine | Synthese de tetra mercaptides stanniques |
| US4472840A (en) | 1981-09-21 | 1984-09-25 | Jefferies Steven R | Method of inducing osseous formation by implanting bone graft material |
| US4559157A (en) | 1983-04-21 | 1985-12-17 | Creative Products Resource Associates, Ltd. | Cosmetic applicator useful for skin moisturizing |
| LU84979A1 (fr) | 1983-08-30 | 1985-04-24 | Oreal | Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux |
| US4820508A (en) | 1987-06-23 | 1989-04-11 | Neutrogena Corporation | Skin protective composition |
| US5606019A (en) | 1987-10-29 | 1997-02-25 | Protien Polymer Technologies, Inc. | Synthetic protein as implantables |
| JP2668259B2 (ja) * | 1988-02-18 | 1997-10-27 | 塩野義製薬株式会社 | 複素環化合物および抗潰瘍剤 |
| GB2215209B (en) | 1988-03-14 | 1992-08-26 | Osmed Inc | Method and apparatus for biodegradable, osteogenic, bone graft substitute device |
| US4992478A (en) | 1988-04-04 | 1991-02-12 | Warner-Lambert Company | Antiinflammatory skin moisturizing composition and method of preparing same |
| US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
| JPH0327172A (ja) | 1989-06-19 | 1991-02-05 | Nissan Chem Ind Ltd | 布の漂白方法 |
| US5645591A (en) | 1990-05-29 | 1997-07-08 | Stryker Corporation | Synthetic bone matrix |
| JPH0741461A (ja) * | 1993-05-27 | 1995-02-10 | Eisai Co Ltd | スルホン酸エステル誘導体 |
| WO2000052001A1 (en) * | 1999-03-03 | 2000-09-08 | Samjin Pharmaceutical Co., Ltd. | Piperazine derivatives and process for the preparation thereof |
| CN1231473C (zh) * | 2000-02-16 | 2005-12-14 | 神经能质公司 | 取代的芳基吡嗪 |
| AU2001288623A1 (en) | 2000-09-05 | 2002-03-22 | Tularik, Inc. | Fxr modulators |
| US20060004010A1 (en) * | 2002-07-10 | 2006-01-05 | Hiromu Habashita | Ccr4 antagonist and medical use thereof |
| EP1529531A1 (en) * | 2003-11-04 | 2005-05-11 | 4Sc Ag | Oxadiazolopyrazine derivatives as pharmaceutically active compounds |
| WO2005044270A1 (en) | 2003-11-04 | 2005-05-19 | 4Sc Ag | Oxadiazolopyrazine derivatives as pharmaceutically active compounds |
| JP2008515979A (ja) * | 2004-10-14 | 2008-05-15 | コンパス ファーマシューティカルズ リミティド ライアビリティ カンパニー | フラザノ‘３，４−ビピラジン（ｂｉｐｙｒａｚｉｎｅ）及び抗腫瘍剤としてのその使用 |
| WO2006124874A2 (en) | 2005-05-12 | 2006-11-23 | Kalypsys, Inc. | Inhibitors of b-raf kinase |
| ES2270715B1 (es) * | 2005-07-29 | 2008-04-01 | Laboratorios Almirall S.A. | Nuevos derivados de pirazina. |
| US8329704B2 (en) * | 2005-12-21 | 2012-12-11 | Janssen Pharmaceutica, N.V. | Substituted pyrazinone derivatives for use in MCH-1 mediated diseases |
| EP2017277A1 (en) * | 2007-06-29 | 2009-01-21 | 4Sc Ag | Thiophene-imidazopyridines |
| CA2709784A1 (en) | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| CA2759795C (en) * | 2009-04-30 | 2016-11-29 | Midwestern University | Method and composition for treating diabetic ketoacidosis |
| EP2604260B1 (en) * | 2010-08-10 | 2017-05-10 | Shionogi&Co., Ltd. | Novel heterocyclic derivatives and pharmaceutical composition containing same |
| RU2014120166A (ru) * | 2011-10-20 | 2015-11-27 | ГЛЭКСОСМИТКЛАЙН ЭлЭлСи | Замещенные бициклические аза-гетероциклы и их аналоги в качестве модуляторов сиртуина |
| KR101481952B1 (ko) * | 2012-04-13 | 2015-01-22 | 한국과학기술연구원 | 신경보호제로서의 유레아 유도체 |
| WO2013192388A1 (en) * | 2012-06-20 | 2013-12-27 | University Of Virginia Patent Foundation | Compositions and methods for regulating glucose homeostasis and insulin action |
| TW201441203A (zh) | 2012-11-05 | 2014-11-01 | Medeia Therapeutics Ltd | Ｎ－取代４－胺苯酚及對應醌亞胺 |
| WO2015000715A1 (en) * | 2013-07-02 | 2015-01-08 | Syngenta Participations Ag | Pesticidally active bi- or tricyclic heterocycles with sulfur containing substituents |
| KR101428622B1 (ko) * | 2014-01-07 | 2014-08-13 | 국방과학연구소 | 옥사디아졸로 피라진기를 포함하는 화합물 또는 염을 포함하는 리튬 이차 전지용 전극 및 이를 포함하는 리튬 이차 전지 |
| MX2017005158A (es) | 2014-10-28 | 2017-07-27 | Shionogi & Co | Derivado heterociclico que tiene actividad de activacion de proteina cinasa activada por adenosina monofostato (ampk). |
| JP2018500388A (ja) * | 2014-11-18 | 2018-01-11 | ラットガーズ、ザ ステート ユニバーシティ オブ ニュージャージー | 代謝疾患及び癌の治療のための、新規ミトコンドリアアンカップラー |
| WO2017151063A1 (en) * | 2016-03-03 | 2017-09-08 | Agency For Science, Technology And Research | Use of furazano[3,4-b]pyrazine derivatives for chemotherapy |
| TWI754702B (zh) * | 2016-12-28 | 2022-02-11 | 德商Ｕｃｂ製藥有限公司 | （氮雜）吲哚－和苯並呋喃－３－磺醯胺類 |
| JP2020520949A (ja) * | 2017-05-22 | 2020-07-16 | ユニバーシティ オブ ヴァージニア パテント ファウンデーションＵｎｉｖｅｒｓｉｔｙ Ｏｆ Ｖｅｒｇｉｎｉａ Ｐａｔｅｎｔ Ｆｏｕｎｄａｔｉｏｎ | 組成物、並びにミトコンドリア脱共役剤を調製及び使用する方法 |
| CN112262141A (zh) * | 2018-04-20 | 2021-01-22 | 弗吉尼亚理工大学知识产权有限公司 | 可用作线粒体解偶联剂的咪唑吡啶 |
-
2019
- 2019-04-22 CN CN201980038722.7A patent/CN112262141A/zh active Pending
- 2019-04-22 JP JP2021506388A patent/JP2021522327A/ja active Pending
- 2019-04-22 KR KR1020207033297A patent/KR20210003831A/ko not_active Withdrawn
- 2019-04-22 MX MX2020011050A patent/MX2020011050A/es unknown
- 2019-04-22 EP EP19735420.2A patent/EP3781572A1/en active Pending
- 2019-04-22 US US17/048,897 patent/US20210253594A1/en not_active Abandoned
- 2019-04-22 CN CN201980038852.0A patent/CN112261941A/zh active Pending
- 2019-04-22 MX MX2020011049A patent/MX2020011049A/es unknown
- 2019-04-22 US US17/049,145 patent/US20210253538A1/en not_active Abandoned
- 2019-04-22 BR BR112020021466-3A patent/BR112020021466A2/pt not_active Application Discontinuation
- 2019-04-22 EP EP19789309.2A patent/EP3781165A4/en not_active Withdrawn
- 2019-04-22 AU AU2019256722A patent/AU2019256722A1/en not_active Abandoned
- 2019-04-22 AU AU2019256719A patent/AU2019256719A1/en not_active Abandoned
- 2019-04-22 WO PCT/US2019/028544 patent/WO2019204813A1/en not_active Ceased
- 2019-04-22 KR KR1020207033337A patent/KR102913366B1/ko active Active
- 2019-04-22 US US17/049,232 patent/US11708376B2/en active Active
- 2019-04-22 JP JP2021506390A patent/JP2021523933A/ja active Pending
- 2019-04-22 BR BR112020021469-8A patent/BR112020021469A2/pt not_active Application Discontinuation
- 2019-04-22 WO PCT/US2019/028560 patent/WO2019204819A1/en not_active Ceased
- 2019-04-22 CA CA3097751A patent/CA3097751A1/en active Pending
- 2019-04-22 JP JP2021506391A patent/JP2021523934A/ja active Pending
- 2019-04-22 CN CN201980038732.0A patent/CN112262146A/zh active Pending
- 2019-04-22 EP EP19735421.0A patent/EP3781567B1/en active Active
- 2019-04-22 KR KR1020207033356A patent/KR102900692B1/ko active Active
- 2019-04-22 CA CA3097752A patent/CA3097752A1/en active Pending
- 2019-04-22 WO PCT/US2019/028555 patent/WO2019204816A1/en not_active Ceased
-
2020
- 2020-10-09 ZA ZA2020/06295A patent/ZA202006295B/en unknown
- 2020-10-09 ZA ZA2020/06296A patent/ZA202006296B/en unknown
- 2020-10-15 IL IL278070A patent/IL278070A/en unknown
- 2020-10-15 IL IL278069A patent/IL278069A/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020011050A (es) | Imidazopiridinas útiles como desacopladores mitocondriales. | |
| GEP20217265B (en) | Glp-1 receptor agonists and uses thereof | |
| SA519401435B1 (ar) | مركبات حلقية ثنائية النيوكليوتيد | |
| CY1120974T1 (el) | Ετεροκυκλικες ενωσεις, φαρμακα που περιεχουν τις αναφερομενες ενωσεις, χρηση αυτων και διαδικασιες για την παραγωγη τους | |
| MX2016010519A (es) | Moleculas para administracion a celulas cancerosas mutantes ros1. | |
| MX386059B (es) | COMPOSICIONES Y SUS usos EN EL TRATAMIENTO DE LA MUCOPOLISACARIDOSIS TIPO I. | |
| CY1117776T1 (el) | Εναντιομερη ενωσεων σπειρο-οξινδολιου και οι χρησεις τους ως θεραπευτικοι παραγοντες | |
| MX2019007071A (es) | Novedosos derivados del acido fenilpropionico y usos de los mismos. | |
| MX2017014584A (es) | Inhibidores heterociclicos de erk1 y erk2 y su uso en el tratamiento del cancer. | |
| BR112017005917A2 (pt) | processos e composições para indução de imunidade protetora contra infecção com o vírus da imunodeficiência humana | |
| CO7170178A2 (es) | Lh-pirazolo[3,4-b]piridinas y usos terapéuticos de las mismas | |
| CO6410287A2 (es) | Composición farmacéutica, forma farmacéutica, procedimiento para su preparación, métodos de tratamiento y usos de la misma | |
| NO20084355L (no) | N-hydroksylsulfonamidderivater som nye fysiologisk anvendelige nitroksyldonorer | |
| MX2020001835A (es) | Métodos para el tratamiento de retinopatía diabética y otras enfermedades oftálmicas. | |
| AR100560A1 (es) | Inhibición o regulación por disminución de la glucógeno sintasa mediante la creación de codones de terminación prematuros utilizando oligonucléotidos antisentido | |
| BR112015021596A2 (pt) | moduladores de gpr120 de ácido oxabiciclo[2.2.2] | |
| AR111188A1 (es) | Terapia génica para el tratamiento de retinitis pigmentosa ligada al gen cngb1 | |
| MX382630B (es) | Compuestos de pirazol disustituidos para el tratamiento de enfermedades. | |
| BR112013030391A2 (pt) | derivados de piperidina 3- espirocíclicos como agonistas dos receptores de grelina | |
| CO2022008606A2 (es) | Derivados de piridopirimidinona como antagonistas de ahr | |
| MX2017003780A (es) | Composicion farmaceutica para tratar colitis ulcerativa. | |
| BR112013019416A2 (pt) | dimaleato de 9-[4-(3-cloro-2-flúor-fenilamino)-7-metóxi-quinazolin-6ilóxi]-1,4-diaza-espiro[5.5]undecan-5-ona, seu uso como medicamento e sua produção | |
| PE20180247A1 (es) | Derivados de pirazol utiles como inhibidores de proteina activadora de 5-lipoxigenasa (flap) | |
| MX2021004185A (es) | Polipeptidos analogos de la amilina humana y sus metodos de uso. | |
| NI201900094A (es) | COMPUESTOS DE TIPO IMIDAZO[4, 5-c]QUINOLIN-2-ONA DEUTERADOS Y SU USO EN EL TRATAMIENTO DEL CÁNCER |